Rheumatoid Arthritis
Clinical trial results generalizable to routine practice
Published in Health and Medicine Week, June 20th, 2005
"Trials of disease-modifying anti-rheumatic drugs (DMARDs) enroll active rheumatoid arthritis patients identified using standard criteria (three out of four of: {{>=}}6 tender joints, {{>=}}6 swollen joints, ESR {{>=}}28 mm/h, {{>=}}45 min morning stiffness)," rheumatologists in England explained.
"Concern has been expressed about generalizability, as many patients in routine practice have less active disease," noted G.H. Kingsley and colleagues at the University of London. "Furthermore, these criteria do not map onto standard...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
More Articles from Health and Medicine Week
- Drug Development
Phenoxypropoxybiguanide analogues show promise as antimalarials - Gene Therapy
Strategies to enhance tumor visibility improve cancer immunotherapy - Psychiatry
Acute day care less expensive than inpatient care in Germany - Stem Cell Research
Stem cell therapy for osteonecrosis may negate the need for hip replacement - Acute Cholangitis
Endoscopic biliary drainage by stent and nasobiliary drain compared - Acute Myeloid Leukemia
Wnt/beta-catenin pathway involved in acute myeloid leukemia pathogenesis - More from this issue of Health and Medicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
